GlassScriptPhysician profile
Lauren Wire
NPI 1033584727
$7,914.48
in general payments reported to CMS, 2019-2025
25 companies · $2,020 in 2025
The $2,020 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $714 · 2022: $1,600 · 2023: $1,502 · 2024: $2,079 · 2025: $2,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,445 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,445.21 |
| Education | $154.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,218.59 | 2021-2025 | Krystexxa, Enbrel, Evenity |
| Abbvie INC. | $1,139.57 | 2021-2025 | |
| Janssen Biotech, INC. | $1,055.22 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Astrazeneca Pharmaceuticals LP | $778.93 | 2021-2025 | Saphnelo |
| Ucb, INC. | $526.61 | 2021-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $406.17 | 2021-2025 | |
| Lilly USA, LLC | $391.54 | 2021-2025 | Taltz |
| Glaxosmithkline, LLC. | $325.93 | 2021-2025 | Benlysta, Nucala |
| Mallinckrodt Hospital Products INC. | $321.59 | 2022-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $264.71 | 2022-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $258.02 | 2023-2025 | Orencia |
| Pfizer INC. | $246.72 | 2021-2025 | |
| Genentech USA, INC. | $190.55 | 2021-2023 | Actemra |
| Actelion Pharmaceuticals US, INC. | $153.53 | 2021-2023 | Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.30 | 2022-2025 | Ofev, Cyltezo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $128.14 | 2022-2024 | |
| Sandoz INC. | $84.66 | 2023-2024 | Hyrimoz |
| Kiniksa Pharmaceuticals, LTD. | $60.81 | 2021-2023 | Arcalyst |
| Radius Health, INC. | $54.16 | 2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $52.75 | 2024 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $29.73 | 2023-2024 | Idacio |
| Ultragenyx Pharmaceutical INC. | $29.15 | 2021-2022 | |
| Mylan Institutional INC. | $23.55 | 2023 | Hulio |
| Kyowa Kirin, INC. | $17.53 | 2025 | |
| Horizon Therapeutics Plc | $16.02 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Wire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.